How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

43,438 results for

antibiotic resistance

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Contact Isolation Precautions for Ambulatory Oncology Patients Positive for Antibiotic Resistant Organisms: A Review of Clinical Effectiveness and Guidelines

Contact Isolation Precautions for Ambulatory Oncology Patients Positive for Antibiotic Resistant Organisms: A Review of Clinical Effectiveness and Guidelines Contact Isolation Precautions for Ambulatory Oncology Patients Positive for Antibiotic Resistant Organisms: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Contact Isolation Precautions for Ambulatory Oncology Patients Positive for Antibiotic Resistant Organisms: A Review of Clinical Effectiveness (...) and Guidelines Contact Isolation Precautions for Ambulatory Oncology Patients Positive for Antibiotic Resistant Organisms: A Review of Clinical Effectiveness and Guidelines Published on: October 6, 2015 Project Number: RC0712-000 Product Line: Research Type: Other Diagnostics Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of contact isolation precautions versus routine infection prevention practices for ambulatory oncology patients

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

62. Universal Screening for Antibiotic-Resistant Organisms in Long-Term Care Facilities

Universal Screening for Antibiotic-Resistant Organisms in Long-Term Care Facilities TITLE: Universal Screening for Antibiotic-Resistant Organisms in Long-Term Care Facilities: Clinical Effectiveness and Guidelines DATE: 18 December 2014 RESEARCH QUESTIONS 1. What is the clinical effectiveness of universal screening for antibiotic-resistant organisms (AROs) upon admission to a long-term care or continuing care facility? 2. What are the evidence-based guidelines regarding screening residents (...) for AROs upon admission to long-term care or continuing care facilities? KEY FINDINGS One systematic review was identified regarding the clinical effectiveness of universal screening for antibiotic-resistant organisms upon admission to a long-term care or continuing care facility. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 12), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

63. Frequency of Rescreening of Patients Negative for Antibiotic Resistant Organisms

Frequency of Rescreening of Patients Negative for Antibiotic Resistant Organisms TITLE: Frequency of Rescreening of Patients Negative for Antibiotic Resistant Organisms: Clinical Evidence and Guidelines DATE: 22 December 2014 RESEARCH QUESTIONS 1. What is the clinical evidence regarding the frequency of rescreening following a negative antibiotic resistant organism (ARO) test result at admission in the acute care setting? 2. What are the evidence-based guidelines regarding the frequency (...) at admission in the acute care setting; therefore, no summary can be provided. Frequency of Rescreening of Patients Negative for Antibiotic Resistant Organisms 2 REFERENCES SUMMARIZED Health Technology Assessments No literature identified. Systematic Reviews and Meta-analyses No literature identified. Randomized Controlled Trials No literature identified. Non-Randomized Studies No literature identified. Guidelines and Recommendations No literature identified. PREPARED BY: Canadian Agency for Drugs

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

64. Frequency of Rescreening of Patients Positive for Antibiotic Resistant Organisms

setting [Internet]. Dublin (IE): Royal College of Physicians of Ireland; 2012 [cited 2014 Dec 19]. Available from: Frequency of Rescreening of Patients Positive for Antibiotic Resistant Organisms 4 http://www.hpsc.ie/A- Z/MicrobiologyAntimicrobialResistance/InfectionControlandHAI/Guidelines/File,12922,en.p df See: Third bullet, page 27 Additional References 11. McGeer A, Fleming CA. Antimicrobial resistance in common hospital pathogens in Ontario: report 2011. Toronto (ON): Ontario Medical Association (...) , Quality Management Program - Laboratory Services; 2012 Apr [cited 2014 Dec 19]. Available from: https://iqmh.org/Portals/0/Docs/Resources/Antimicrobial%20Resistance%20Report%2020 11.pdf See: 63. When are precautions discontinued?, page 23 Frequency of Rescreening of Patients Positive for Antibiotic Resistant Organisms 5

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

65. Contact Precautions for Patients Previously Positive for Antibiotic Resistant Organisms

Contact Precautions for Patients Previously Positive for Antibiotic Resistant Organisms TITLE: Contact Precautions for Patients Previously Positive for Antibiotic Resistant Organisms: Guidelines DATE: 05 January 2015 RESEARCH QUESTION What are the evidence-based guidelines regarding the management of patients in acute care who have previously tested positive, but are currently negative for antibiotic resistant organisms? KEY FINDINGS No evidence-based guidelines were identified regarding (...) the management of patients in acute care who have previously tested positive, but are currently negative for antibiotic resistant organisms. METHODS A limited literature search was conducted on key resources including PubMed, Medline, The Cochrane Library (2014, Issue 12), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to health

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

66. Development of Antibiotic Resistance to Norfloxacin in the Treatment of Urinary Tract Infections

tract infections in relation to demographic and clinical data. Clin Microbiol Infect. 2005 Mar;11(3):199-203. PubMed: PM15715717 PREPARED BY: Canadian Agency for Drugs and Technologies in Health Tel: 1-866-898-8439 www.cadth.ca Development of Antibiotic Resistance to Norfloxacin in the Treatment of UTIs 3 APPENDIX – FURTHER INFORMATION: Non-Randomized Studies Population Level Resistance Over Time 2. Orrett FA, Davis GK. A comparison of antimicrobial susceptibility profile of urinary pathogens (...) Development of Antibiotic Resistance to Norfloxacin in the Treatment of Urinary Tract Infections Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

67. Antibiotic resistance profiles of deep surgical site infections in hip hemiarthroplasty; comparing low dose single antibiotic versus high dose dual antibiotic impregnated cement Full Text available with Trip Pro

Antibiotic resistance profiles of deep surgical site infections in hip hemiarthroplasty; comparing low dose single antibiotic versus high dose dual antibiotic impregnated cement Objectives: The incidence of fractured neck of femur (FNOF) is increasing yearly. Many of these patients undergo hip hemiarthroplasty. High dose dual-antibiotic cement (HDDAC) has been shown to reduce rates of deep surgical site infection (SSI) when compared to the current standard low dose single-antibiotic cement (...) (LDSAC) in a quasi-randomised controlled trial. Some concerns exist regarding the use of HDDAC and the development of antibiotic resistance. We reviewed cases of infection in LDSAC and HDDAC bone cement with regard to causative organism and resistance profile. Methods: A retrospective analysis was undertaken of all hemiarthroplasties within our trust from April 2008 to December 2014. We identified all patients in this time period who acquired a deep SSI. The infecting organisms and susceptibility

2018 Journal of Bone and Joint Infection

68. A horizontally gene transferred copper resistance locus confers hyper‐resistance to antibacterial copper toxicity and enables survival of community acquired methicillin resistant Staphylococcus aureus USA300 in macrophages Full Text available with Trip Pro

A horizontally gene transferred copper resistance locus confers hyper‐resistance to antibacterial copper toxicity and enables survival of community acquired methicillin resistant Staphylococcus aureus USA300 in macrophages Excess copper is highly toxic and forms part of the host innate immune system's antibacterial arsenal, accumulating at sites of infection and acting within macrophages to kill engulfed pathogens. We show for the first time that a novel, horizontally gene transferred copper (...) lipoprotein, confer copper hyper-resistance compared to typical S. aureus strains. The copXL genes form an operon that is tightly repressed in low copper environments by the copper regulator CsoR. Significantly, CopX and CopL are important for S. aureus USA300 intracellular survival within macrophages. Therefore, the emergence of new S. aureus clones with the copXL locus has significant implications for public health because these genes confer increased resistance to antibacterial copper toxicity

2018 Environmental microbiology

69. Perioperative antibiotics for preventing post-surgical site infections in solid organ transplant recipients. Full Text available with Trip Pro

antibiotics in preventing surgical site infections in solid organ transplant recipients at any time point after transplantation.Two authors independently determined study eligibility, assessed quality, and extracted data. Primary outcomes were surgical site infections and antimicrobial resistance. Other outcomes included urinary tract infections, pneumonias and septicaemia, death (any cause), graft loss, graft rejection, graft function, adverse reactions to antimicrobial agents, and outcomes identified (...) Perioperative antibiotics for preventing post-surgical site infections in solid organ transplant recipients. Solid organ transplant recipients are at high risk for infections due to the complexity of surgical procedures combined with the impact of immunosuppression. No consensus exists on the role of antibiotics for surgical site infections in solid organ transplant recipients.To assess the benefits and harms of prophylactic antimicrobial agents for preventing surgical site infections in solid

2020 Cochrane

70. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. (Abstract)

and near-significant reductions in Pseudomonas aeruginosa, but the quality of this evidence is again very low.We could not identify an antibiotic adjuvant therapy that we could recommend for treating of lung infection in people with cystic fibrosis. The emergence of increasingly resistant bacteria makes the reliance on antibiotics alone challenging for cystic fibrosis teams. There is a need to explore alternative strategies, such as the use of adjuvant therapies. Further research is required to provide (...) Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Cystic fibrosis is a multi-system disease characterised by the production of thick secretions causing recurrent pulmonary infection, often with unusual bacteria. This leads to lung destruction and eventually death through respiratory failure. There are no antibiotics in development that exert a new mode of action and many of the current antibiotics are ineffective in eradicating the bacteria once chronic infection

2020 Cochrane

71. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Full Text available with Trip Pro

aureus versus no prophylaxis in people with cystic fibrosis, we tested the following hypotheses to investigate whether prophylaxis: 1. improves clinical status, lung function and survival; 2. leads to fewer isolates of Staphylococcus aureus; 3. causes adverse effects (e.g. diarrhoea, skin rash, candidiasis); 4. leads to fewer isolates of other common pathogens from respiratory secretions; 5. leads to the emergence of antibiotic resistance and colonisation of the respiratory tract with Pseudomonas (...) Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Staphylococcus aureus causes pulmonary infection in young children with cystic fibrosis. Prophylactic antibiotics are prescribed hoping to prevent such infection and lung damage. Antibiotics have adverse effects and long-term use might lead to infection with Pseudomonas aeruginosa. This is an update of a previously published review.To assess continuous oral antibiotic prophylaxis to prevent the acquisition of Staphylococcus

2020 Cochrane

72. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. (Abstract)

are resistant to many common antibiotics and able to acquire resistance against many more. Following patient segregation in cystic fibrosis medical care, the more virulent epidemic strains are not as frequent, and new infections are more likely to be with less virulent environmentally-acquired strains. Although evidence-based guidelines exist for treating respiratory exacerbations involving Pseudomonas aeruginosa, these cannot be extended to Burkholderia cepacia complex infections. This review, which (...) Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Chronic pulmonary infection is a hallmark of lung disease in cystic fibrosis. Infections dominated by organisms of the Burkholderia cepacia complex, a group of at least 18 closely-related species of gram-negative bacteria, are particularly difficult to treat. These infections may be associated with a fulminant necrotising pneumonia. Burkholderia cepacia complex bacteria

2020 Cochrane

73. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. (Abstract)

Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. Stenotrophomonas maltophilia is one of the most common emerging multi-drug resistant organisms found in the lungs of people with cystic fibrosis and its prevalence is increasing. Chronic infection with Stenotrophomonas maltophilia has recently been shown to be an independent predictor of pulmonary exacerbation requiring hospitalization and antibiotics. However, the role of antibiotic treatment (...) of Stenotrophomonas maltophilia infection in people with cystic fibrosis is still unclear. This is an update of a previously published review.The objective of our review is to assess the effectiveness of antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. The primary objective is to assess this in relation to lung function and pulmonary exacerbations in the setting of acute pulmonary exacerbations. The secondary objective is to assess this in relation to the eradication

2020 Cochrane

74. Exploration of antibiotic resistance risks in a veterinary teaching hospital with Oxford Nanopore long read sequencing. Full Text available with Trip Pro

Exploration of antibiotic resistance risks in a veterinary teaching hospital with Oxford Nanopore long read sequencing. The Oxford Nanopore MinION DNA sequencing device can produce large amounts of long sequences, typically several kilobases, within a few hours. This long read capacity was exploited to detect antimicrobial resistance genes (ARGs) in a large veterinary teaching hospital environment, and to assess their taxonomic origin, genetic organisation and association with mobilisation (...) markers concurrently. Samples were collected on eight occasions between November 2016 and May 2017 (inclusive) in a longitudinal study. Nanopore sequencing was performed on total DNA extracted from the samples after a minimal enrichment step in broth. Many ARGs present in the veterinary hospital environment could potentially confer resistance to antimicrobials widely used in treating infections of companion animals, including aminoglycosides, extended-spectrum beta-lactams, sulphonamides, macrolides

2019 PLoS ONE

75. Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus. Full Text available with Trip Pro

Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus. The recent emergence of antibiotic-resistant bacteria requires the development of new antibiotics or new agents capable of enhancing antibiotic activity. This study evaluated the antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii (...) and methicillin-resistant Staphylococcus aureus (MRSA), which should resolve the problem of antibiotic-resistant bacteria. Bactericidal tests showed that LYZOX killed 50% more P. aeruginosa (NBRC 13275), A. baumannii and MRSA than the control treatment after 60 min. In addition, LYZOX was shown to inhibit the growth of P. aeruginosa (NBRC 13275 and PAO1), A. baumannii and MRSA better than its components. To elucidate the antibacterial mechanism of LYZOX, we performed cell membrane integrity assays, N-phenyl-1

2019 PLoS ONE

76. Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma. Full Text available with Trip Pro

Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma. The emergence of Mycobacterium tuberculosis strains resistant to current first-line antibiotic regimens constitutes a major global health threat. New treatments against multidrug-resistant tuberculosis (MDR-TB) are thus eagerly needed in particular in countries with a high MDR

2019 PLoS ONE

77. Detection of critical antibiotic resistance genes through routine microbiome surveillance. Full Text available with Trip Pro

Detection of critical antibiotic resistance genes through routine microbiome surveillance. Population-based public health data on antibiotic resistance gene carriage is poorly surveyed. Research of the human microbiome as an antibiotic resistance reservoir has primarily focused on gut associated microbial communities, but data have shown more widespread microbial colonization across organs than originally believed, with organs previously considered as sterile being colonized. Our study (...) demonstrates the utility of postmortem microbiome sampling during routine autopsy as a method to survey antibiotic resistance carriage in a general population. Postmortem microbial sampling detected pathogens of public health concern including genes for multidrug efflux pumps, carbapenem, methicillin, vancomycin, and polymixin resistances. Results suggest that postmortem assessments of host-associated microbial communities are useful in acquiring community specific data while reducing selective-participant

2019 PLoS ONE

78. Persistence of antibiotic resistance genes in beef cattle backgrounding environment over two years after cessation of operation. Full Text available with Trip Pro

Persistence of antibiotic resistance genes in beef cattle backgrounding environment over two years after cessation of operation. Confined animal feeding operations can facilitate the spread of genes associated with antibiotic resistance. It is not known how cattle removal from beef cattle backgrounding operation affects the persistence of antibiotic resistance genes (ARGs) in the environment. We investigated the effect of cessation of beef cattle backgrounding operation on the persistence (...) . Metagenomic DNA was extracted from the soil samples and total bacterial population (16S rRNA), total Enterococcus species and class 1 integrons (intI1), and erythromycin (ermB and ermF), sulfonamide (sul1 and sul2) and tetracycline (tetO, tetW and tetQ) resistance genes were quantified. Concentrations of total bacteria, Enterococcus spp., class 1 integrons, and ARGs were higher in the feeding area and its immediate vicinity (around the fence and the gate) followed by a gradient decline along the grazing

2019 PLoS ONE

79. Correction: Pneumococcal carriage among sickle cell disease patients in Accra, Ghana: Risk factors, serotypes and antibiotic resistance. Full Text available with Trip Pro

Correction: Pneumococcal carriage among sickle cell disease patients in Accra, Ghana: Risk factors, serotypes and antibiotic resistance. [This corrects the article DOI: 10.1371/journal.pone.0206728.].

2019 PLoS ONE

80. Correction: Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis. Full Text available with Trip Pro

Correction: Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis. [This corrects the article DOI: 10.1371/journal.pone.0172179.].

2019 PLoS ONE

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>